Form D · Biotechnology
Silenseed Ltd.
Jerusalem, L3 · CIK 0001602634
Offering snapshot reported Apr 8, 2014 · SEC filing
- Reported sold
- $500K Offering amount: $500K
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 25, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 8, 2014 | Initial | $500,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-215152
Sold 7,621 ordinary-1 shares and warrantsto purchase up to 7,621 ordinary shares.
Source: Form D, filed Apr 8, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Shmuel Cabilly | Director |
| Eithan Galun | Director |
| Amotz Shemi | Director, Executive |
| Ilan Shiloah | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Goldyne Savad Institute Of Gene Therapy Hadassah Medical Center Ein Kerem
Jerusalem, L3, 9112001
Jerusalem, L3, 9112001